Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Blood (2023) 142 (Supplement 1): 4879.

https://doi.org/10.1182/blood-2023-174477

Published: 2023

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Nieves Lopez-Muñoz

Blood (2023) 142 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2023-182141

Published: 2023

Journal Articles

Applying Artificial Intelligence Machine Learning to Discover Factors That Shorten Duration of Treatment in Patients with Multiple Myeloma Using Real-World Patient-Level Longitudinal Data from Medical Data Vision Database

Hiroshi Handa, Tadao Ishida, Shuji Ozaki, Shinsuke Iida, Asuka Mori, Chika Sakai, Kenichi Kato, David Bin-Chia Wu, DaeYoung Yu, Shota Nemoto, Yasuho Yamashita, Takuma Shibahara

Blood (2023) 142 (Supplement 1): 6665.

https://doi.org/10.1182/blood-2023-172849

Published: 2023

Journal Articles

Real-World Clinical Outcomes in Patients with Relapse and Refractory Multiple Myeloma Received VTD-PACE Treatment in the Era of Monoclonal Antibody

Moe Yogo, Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Yuki Okda, Kota Sato, Mizuki Ogura, Tomomi Takei, Yu ABE, Kenshi Suzuki, Tadao Ishida

Blood (2023) 142 (Supplement 1): 6625.

https://doi.org/10.1182/blood-2023-174725

Published: 2023

Journal Articles

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Blood (2021) 138 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2021-145483

Published: 2021

Journal Articles

Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma

Mizuki Ogura, MDPhD, Tadao Ishida, MDPhD, Moe Nomura, Hirofumi Irita, Junichiro Nashimoto, Kota Sato, MDPhD, Kanji Miyazaki, MDPhD, Yu Abe, MD, Nobuhiro Tsukada, MDPhD, Kenshi Suzuki, MD PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-143459

Published: 2020

Journal Articles

The Clinical Features of Multiple Myeloma with AL Amyloidosis

Junichiro Nashimoto, Moe Nomura, Hirofumi Irita, Kota Sato, MDPhD, Kanji Miyazaki, MDPhD, Mizuki Ogura, MDPhD, Yu Abe, MD, Nobuhiro Tsukada, MDPhD, Tadao Ishida, MDPhD, Kenshi Suzuki, MD PhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-142362

Published: 2020

Journal Articles

MRD Detection in Myeloma Cells: Comparison between Inexpensive 1-Tube 10 Color Multiparameter Flow Cytometry and Euroflow Multiparameter Flow Cytometry

Kiyoshi Okazuka, MD, Tadao Ishida, MD PhD, Jun Sakamoto, Nobuhiro Tsukada, MD PhD, Kenshi Suzuki, MD PhD

Blood (2019) 134 (Supplement_1): 1832.

https://doi.org/10.1182/blood-2019-123900

Published: 2019

Journal Articles

Identification of Clonal Immunoglobulin λ Light-Chain Gene Rearrangements in AL Amyloidosis Using Next Generation Sequencing

Blood (2019) 134 (Supplement_1): 1748.

https://doi.org/10.1182/blood-2019-125028

Published: 2019

Journal Articles

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD PhD, Kazutaka Sunami, MD PhD, Tadao Ishida, MD PhD, Kenshi Suzuki, MD PhD, Tomoko Narita, MD, Shinsuke Iida, MD PhD, Yuichi Nakamura, MD PhD, Kazuhito Suzuki, MD, Noriko Nishimura, MD PhD, Hirokazu Murakami, MD PhD, Kazuyuki Shimizu, MD

Blood (2019) 134 (Supplement_1): 3085.

https://doi.org/10.1182/blood-2019-125390

Published: 2019

Journal Articles

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Takahiko Murayama, PhD, Kota Sato, MD PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Muneyoshi Futami, MD PhD, Masaki Ri, Hiroshi Yasui, MD PhD, Noriko Gotoh, MD, Shinsuke Iida, MD PhD, Tadao Ishida, MD PhD, Hiroshi Handa, MD PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 4325.

https://doi.org/10.1182/blood-2019-122662

Published: 2019

Journal Articles

Retrospective Analysis of the Efficacy and Safety of Modified Bortezomib-Lenalidomide-Dexamethasonelite (modified RVD-lite) Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Kiyoshi Okazuka, MD, Tadao Ishida, MDPhD, Junichiro Nashimoto, MD, Takao Yogo, MD, Kanji Miyazaki, MD, Kota Sato, MDPhD, Yui Uto, MD PhD, Mizuki Ogura, MDPhD, Yumiko Yoshiki, MDPhD, Yu ABE, MD, Nobuhiro Tsukada, MDPhD, Kenshi Suzuki, MD PhD

Blood (2018) 132 (Supplement 1): 1961.

https://doi.org/10.1182/blood-2018-99-112294

Published: 2018

Journal Articles

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Blood (2017) 130 (Supplement 1): 5432.

https://doi.org/10.1182/blood.V130.Suppl_1.5432.5432

Published: 2017

Journal Articles

Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases

Kiyoshi Okazuka, MD, Nobuhiro Tsukada, Kota Sato, MD, Kanji Miyazaki, Yumiko Yoshiki, Yu Abe, MD, Tadao Ishida, MD, Kenshi Suzuki

Blood (2017) 130 (Supplement 1): 4542.

https://doi.org/10.1182/blood.V130.Suppl_1.4542.4542

Published: 2017

Journal Articles

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

Blood (2017) 130 (Supplement 1): 3121.

https://doi.org/10.1182/blood.V130.Suppl_1.3121.3121

Published: 2017

Journal Articles

10 Years History of Cost-Effectiveness for 209 Newly Diagnosed Multiple Myeloma Patients at a Single-Institute in Japan

Kenshi Suzuki, MD PhD, Tomofumi Yamamoto, Masahiro Ikeda, MD, Tomomi Takei, MD, Nobuhiro Tsukada, MD PhD, Tadao Ishida, MD PhD, Arimi Ueda, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD

Blood (2016) 128 (22): 5620.

https://doi.org/10.1182/blood.V128.22.5620.5620

Published: 2016

Journal Articles

The Trifunctional Antibody (tri-31C2) Targeting CD38 and CD3 Has a Stronger Anti-Myeloma Effect Than the Chimeric Anti-CD38 Monoclonal Antibody (ch-31C2)

Tadao Ishida, MD PhD, Hiroshi Yasui, MD PhD, Kazuya Ishiguro, MD, Yuka Aoki, MD PhD, Hiroshi Ikeda, MD PhD

Blood (2016) 128 (22): 2097.

https://doi.org/10.1182/blood.V128.22.2097.2097

Published: 2016

Journal Articles

Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.

Tadao Ishida, MD, Hideo Kimura, MD PhD, Koumei Kubo, MD, Kazutaka Sunami, MD, Shuji Ozaki, MD, Naoki Takezako, MD, Hiroshi Handa, MD PhD, Hiroshi Kosugi, MD, Hirokazu Murakami, MD, Kazuyuki Shimizu, MD

Blood (2015) 126 (23): 3043.

https://doi.org/10.1182/blood.V126.23.3043.3043

Published: 2015

Journal Articles

Addition of Bortezomib to Melphalan Plus Dexamethasone Provides Rapid Response in AL Amyloidosis

Toshiaki Hayashi, MD PhD, Tetsuyuki Igarashi, MD, Hiroshi Ikeda, MD PhD, Mitsufumi Nishio, MD PhD, Tadao Ishida, MD PhD, Yasuhisa Shinomura, MD PhD

Blood (2014) 124 (21): 5766.

https://doi.org/10.1182/blood.V124.21.5766.5766

Published: 2014

NARROW

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Applying Artificial Intelligence Machine Learning to Discover Factors That Shorten Duration of Treatment in Patients with Multiple Myeloma Using Real-World Patient-Level Longitudinal Data from Medical Data Vision Database

Real-World Clinical Outcomes in Patients with Relapse and Refractory Multiple Myeloma Received VTD-PACE Treatment in the Era of Monoclonal Antibody

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma

The Clinical Features of Multiple Myeloma with AL Amyloidosis

MRD Detection in Myeloma Cells: Comparison between Inexpensive 1-Tube 10 Color Multiparameter Flow Cytometry and Euroflow Multiparameter Flow Cytometry

Identification of Clonal Immunoglobulin λ Light-Chain Gene Rearrangements in AL Amyloidosis Using Next Generation Sequencing

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Retrospective Analysis of the Efficacy and Safety of Modified Bortezomib-Lenalidomide-Dexamethasonelite (modified RVD-lite) Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

10 Years History of Cost-Effectiveness for 209 Newly Diagnosed Multiple Myeloma Patients at a Single-Institute in Japan

The Trifunctional Antibody (tri-31C2) Targeting CD38 and CD3 Has a Stronger Anti-Myeloma Effect Than the Chimeric Anti-CD38 Monoclonal Antibody (ch-31C2)

Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.

Addition of Bortezomib to Melphalan Plus Dexamethasone Provides Rapid Response in AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only